We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

183 hedge funds and large institutions have $1.39B invested in KalVista Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 63 increasing their positions, 45 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 16

84% more call options, than puts

Call options by funds: $39.1M | Put options by funds: $21.2M

80% more funds holding in top 10

Funds holding in top 10: 5 → 9 (+4)

40% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 45

29% more capital invested

Capital invested by funds: $1.08B → $1.39B (+$313M)

14% more funds holding

Funds holding: 161 → 183 (+22)

2.77% more ownership

Funds ownership: 132.43% → 135.2% (+2.8%)

Holders
183
Holders Change
+22
Holders Change %
+13.66%
% of All Funds
2.25%
Holding in Top 10
9
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+80%
% of All Funds
0.11%
New
41
Increased
63
Reduced
45
Closed
16
Calls
$39.1M
Puts
$21.2M
Net Calls
+$17.9M
Net Calls Change
+$11.5M

Top Buyers

Rank Fund Capital Flow
1
DCM
Driehaus Capital Management
Illinois
+$9.09M
2
SSC
Spruce Street Capital
New York
+$8.22M
3
SCM
Silverarc Capital Management
Massachusetts
+$7.24M
4
AC
Armistice Capital
New York
+$7.03M
5
CCM
Catalio Capital Management
New York
+$6.87M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$15.9M
2
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
-$10.7M
3
WP
Woodline Partners
California
-$6.63M
4
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB)
Sweden
-$5.68M
5
O
OrbiMed
New York
-$4.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
CA
176
Clearstead Advisors
Ohio
$972 +$161 +10 +26%
PWA
177
Physician Wealth Advisors
Utah
$906 – – –
PFBT
178
Parkside Financial Bank & Trust
Missouri
$805 – – –
EP
179
Essential Partners
California
$403 – – –
KFAS
180
Keating Financial Advisory Services
Kansas
$322 +$258 +16 New
SS
181
Sunbelt Securities
Texas
$181 – – –
HFS
182
Hughes Financial Services
Virginia
$81 +$48 +3 +300%
Skandinaviska Enskilda Banken (SEB)
183
Skandinaviska Enskilda Banken (SEB)
Sweden
– -$5.68M -351,305 Closed
Renaissance Technologies
184
Renaissance Technologies
New York
– -$2.67M -165,151 Closed
CM
185
Caption Management
Oklahoma
– -$1.9M -117,907 Closed
JF
186
Jump Financial
Illinois
– -$1.47M -90,742 Closed
A
187
AlphaQuest
New York
– -$843K -52,190 Closed
Jane Street
188
Jane Street
New York
– -$509K -31,608 Closed
ACM
189
Aquatic Capital Management
Illinois
– -$377K -23,370 Closed
AG
190
Algert Global
California
– -$212K -13,110 Closed
IIM
191
INTECH Investment Management
Florida
– -$209K -12,919 Closed
MF
192
Magnetar Financial
Illinois
– -$177K -10,938 Closed
Group One Trading
193
Group One Trading
Illinois
– -$61K -3,777 Closed
AB
194
Amalgamated Bank
New York
– -$19K -1,205 Closed
ACM
195
Aster Capital Management
United Arab Emirates
– -$4.49K -278 Closed
AAP
196
Arax Advisory Partners
Colorado
– -$4.04K -250 Closed
Daiwa Securities Group
197
Daiwa Securities Group
Japan
– -$2K -154 Closed
GAMC
198
Garner Asset Management Corp
Texas
– -$2.18K -135 Closed
4 5 6 7
8

KALV Hedge Fund Activity: Q1 2026 in Review

183 of the 8,133 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2026, worth a combined $1.39B — up 29% from $1.08B a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new KALV positions and 16 closed out — a net gain of 25 holders — while 63 added to existing stakes and 45 trimmed.

The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $9.09M. The largest seller was Millennium Management, cutting an estimated $15.9M.

  • 183 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2026, up from 161 in Q4 2025.
  • Funds reported $1.39B of KalVista Pharmaceuticals stock for Q1 2026, up 29% quarter-over-quarter.
  • 41 funds opened new KalVista Pharmaceuticals positions in Q1 2026 and 16 closed out, a net change of +25 holders.
  • The largest KalVista Pharmaceuticals buyer in Q1 2026 was Driehaus Capital Management, an estimated $9.09M added.
  • The largest KalVista Pharmaceuticals seller in Q1 2026 was Millennium Management, an estimated $15.9M sold.

Based on aggregated 13F filings for Q1 2026.